MethylGene Inc.

MethylGene Inc.

March 01, 2005 09:49 ET

MethylGene Year End Results Conference Call Notice


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: METHYLGENE INC.

TSX SYMBOL: MYG

MARCH 1, 2005 - 09:49 ET

MethylGene Year End Results Conference Call Notice

MONTREAL, QUEBEC--(CCNMatthews - March 1, 2005) - MethylGene Inc.
(TSX:MYG) will release its results for the fiscal year ending December
31, 2004 prior to market open on March 9th, 2005 and will host a
conference call to discuss its year end results on the same day at 4:30
pm EST. MethylGene would like to invite all interested parties to
participate by dialing 416-640-4127 or 1-800-814-3911. You will be put
on hold until the conference call begins.



On the call from MethylGene will be:

Donald F. Corcoran President and CEO
Klaus Kepper Vice-President Finance and CFO
Dr. Jeffrey M. Besterman Senior Vice-President, R&D


A question and answer session will follow, at which time the operator
will direct participants as to the correct procedure for submitting
questions.

A live audio webcast of the conference call will be available at
www.methylgene.com.

A telephone replay of the conference call will also be available on
March 9th 2005 through March 16th, 2005. To access the replay, dial
416-640-1917 or 1-877-289-8525 and enter reservation number 21115369.

About MethylGene

MethylGene is a publicly traded biopharmaceutical company focused on the
discovery, development and commercialization of novel therapeutics in
cancer and infectious disease. Two cancer product candidates, MG98,
partnered with MGI Pharma for North America and MGCD0103, partnered with
Taiho Pharmaceutical for certain Asian countries, are currently in
clinical trials.

MG98 has entered a randomized two-step Phase II combination trial with
interferon alpha in metastatic renal cell cancer. MGCD0103 is currently
in Phase I dose-escalation monotherapy trials against solid tumours and
hematological malignancies. In collaboration with Merck, MethylGene is
developing small molecule beta-lactamase inhibitors to overcome
antibiotic resistance. MethylGene has a portfolio of preclinical
programs for its kinase and histone deacetylase (HDAC) inhibitors for
both oncology and non-oncology indications, and is exploiting its core
HDAC expertise for the treatment of neurodegenerative diseases with
EnVivo Pharmaceuticals. Please visit MethylGene's website at
www.methylgene.com.

-30-

Contact Information